Show simple item record

dc.contributor.authorEllis, MJ
dc.contributor.authorSuman, VJ
dc.contributor.authorHoog, J
dc.contributor.authorGoncalves, R
dc.contributor.authorSanati, S
dc.contributor.authorCreighton, CJ
dc.contributor.authorDeSchryver, K
dc.contributor.authorCrouch, E
dc.contributor.authorBrink, A
dc.contributor.authorWatson, M
dc.contributor.authorLuo, J
dc.contributor.authorTao, Y
dc.contributor.authorBarnes, M
dc.contributor.authorDowsett, M
dc.contributor.authorBudd, GT
dc.contributor.authorWiner, E
dc.contributor.authorSilverman, P
dc.contributor.authorEsserman, L
dc.contributor.authorCarey, L
dc.contributor.authorMa, CX
dc.contributor.authorUnzeitig, G
dc.contributor.authorPluard, T
dc.contributor.authorWhitworth, P
dc.contributor.authorBabiera, G
dc.contributor.authorGuenther, JM
dc.contributor.authorDayao, Z
dc.contributor.authorOta, D
dc.contributor.authorLeitch, M
dc.contributor.authorOlson, JA
dc.contributor.authorAllred, DC
dc.contributor.authorHunt, K
dc.date.accessioned2017-05-03T13:58:50Z
dc.date.issued2017-04
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 35 (10), pp. 1061 - 1069
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/630
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.2016.69.4406
dc.description.abstractPurpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole. For the trial ACOSOG Z1031B, the protocol was amended to include a tumor Ki67 determination after 2 to 4 weeks of AI. If the Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy. A pCR rate of > 20% was the predefined efficacy threshold. In patients who completed neoadjuvant AI, stratified Cox modeling was used to assess whether time to recurrence differed by PEPI = 0 score (T1 or T2, N0, Ki67 < 2.7%, ER Allred > 2) versus PEPI > 0 disease. Results Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI, 0.7% to 19.1%). After 5.5 years of median follow-up, four (3.7%) of the 109 patients with a PEPI = 0 score relapsed versus 49 (14.4%) of 341 of patients with PEPI > 0 (recurrence hazard ratio [PEPI = 0 v PEPI > 0], 0.27; P = .014; 95% CI, 0.092 to 0.764). Conclusion Chemotherapy efficacy was lower than expected in ER-positive tumors exhibiting AI-resistant proliferation. The optimal therapy for these patients should be further investigated. For patients with PEPI = 0 disease, the relapse risk over 5 years was only 3.6% without chemotherapy, supporting the study of adjuvant endocrine monotherapy in this group. These Ki67 and PEPI triage approaches are being definitively studied in the ALTERNATE trial (Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment in Postmenopausal Women: A Phase III Study; clinical trial information: NCT01953588).
dc.formatPrint-Electronic
dc.format.extent1061 - 1069
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectNeoplasm Recurrence, Local
dc.subjectNitriles
dc.subjectTriazoles
dc.subjectAndrostadienes
dc.subjectKi-67 Antigen
dc.subjectReceptors, Estrogen
dc.subjectReceptors, Progesterone
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAromatase Inhibitors
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectNeoadjuvant Therapy
dc.subjectMitotic Index
dc.subjectSurvival Rate
dc.subjectProportional Hazards Models
dc.subjectFollow-Up Studies
dc.subjectPredictive Value of Tests
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectTranscriptome
dc.subjectClinical Decision-Making
dc.subjectLetrozole
dc.subjectAnastrozole
dc.titleKi67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
dc.typeJournal Article
dcterms.dateAccepted2016-12-14
rioxxterms.versionofrecord10.1200/jco.2016.69.4406
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2017-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume35
pubs.embargo.termsNot known
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0